From the Neuro-Oncology Volume 20 Issue suppl_6 November 2018
"The phase 2 component will evaluate clinical activity of GDC-0084 at the RP2D vs temozolomide as adjuvant therapy following surgical resection and chemoradiation in 224 patients."
https://academic.oup.com/neuro-onco.../suppl_6/vi23/5154299?redirectedFrom=fulltext
Two question for us all.
One, I suppose the longer the part A take for the new MTD the better? Meaning a higher dose with no serve AE is great all round for the next part of the trial.
Two with 224 patients in the next stage....well that is going to take some gold coin indeed. It seems from much correspondence and the investor presentation they seem so confident of the process. In fact the last CR they seemed to want it targeted to only just get to this next stage to stop investor dilution. So what is everyones thoughts on where the big bucks are going to come from. Gov grants. Deals. Partnership. ?????
Phase II b
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
